Skip to main content

Table 3 Total number of patients, years at risk and AEs leading to discontinuation

From: Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study

  July/03-Oct/05 Oct/05-Dec/07
Total number of patients 301 301
Number of AEs resulting in discontinuation 3 44
Number of patient months at risk 20492 9929
Rate of AEs per patient-months-at-risk 0.0001** 0.0044**
  1. AE: adverse event; **Difference between two periods is significant at p < 0.001 level